COMP <GO>
ACRS vs IRWD // EV/EBITDA & P/E VALUATION
Aclaris Therapeutics Inc. (NASDAQ) VS. Ironwood Pharmaceuticals Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: ACRS 2
— IRWD 6
■ METRIC PARITY
LAST: $3.80 (-4.28%) • MKT CAP: $584.4M
valuation
—
LAST: $3.46 (-1.14%) • MKT CAP: $578.3M
valuation
3.9x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACRS VS. IRWD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACRS | IRWD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 73.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 85.00% | -120.00 | IRWD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 3.9x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.04% | 21.23% | -29.27 | IRWD | /fcf-yield <GO> |
| Operating Margin | -60.00% | 33.30% | -93.30 | IRWD | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 8.10% | -68.10 | IRWD | /net-margins <GO> |
| Revenue Growth (YoY) | -58.20% | -15.70% | -42.50 | IRWD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.20 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | IRWD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.6 | 41.9 | +3.70 | ACRS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.2x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $584.4M | $578.3M | $6.0M | ACRS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACRS REV | IRWD REV | ACRS GROSS % | IRWD GROSS % | ACRS FCF | IRWD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $7.8M | $296.2M | 73.3% | — | -$47.2M | $127.0M |
| FY 2024 | $18.7M | $351.4M | 85.1% | — | -$20.2M | $103.4M |
| FY 2023 | $31.2M | $442.7M | — | — | -$78.3M | $183.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACRS // BETA —
IRWD // BETA —